Mechanobiology-based medicine / Mechanomeds
Lead Research Organisation:
University of Glasgow
Department Name: School of Engineering
Abstract
Nowadays diagnosis is largely enabled by the identification of molecular markers associated with the onset of a pathological state. Nevertheless, many diseases escape this paradigm, as the biochemical fingerprint of the aberrant cells do not differ significantly from healthy ones, hindering early diagnosis and reducing the impact of treatments. One prototypical example is Leukaemia, a type of cancer that kills more than 300,000 people in the world every year. The evolution of the disease happens as we get older, but there is now evidence that cells in our body progress towards a malignant phenotype many years before they can be identified with current diagnostic techniques. This proposal will exploit mechanobiology, a field of research that has progressed in the last 10 years, as a novel method to interrogate very early changes in cellular state, bringing it closer to medical use by combining advanced biomaterials, novel microscopy techniques and robotics. Mechanobiology has taught us that cells can feel and react to their mechanical environment. For example, cancer cells are softer than normal cells. However, reorganisation of their niche causes increased tissue stiffness. Here, we will use mechanical stimulation to interrogate cells potential to become cancer cells. Cell response to these external mechanical stimuli will reveal their potential to evolve from health to disease.
We will focus on leukaemia, a cancer that originates in the bone marrow, as normal haematopoietic stem cells, which play the essential role of making our blood, start a malignant transformation giving rise to leukemic stem cells. We have demonstrated that healthy cells and pre-malignant/malignant cells respond differently to mechanical stimulation. This project will develop an in vitro model of the bone marrow using soft hydrogels with defined mechanical and biochemical properties that host mesenchymal stem cells and hematopoietic (or leukemic) stem cells, as are found together in the marrow. We will investigate how external mechanical stimulation of the model using nanoscale vibration of controlled frequency and amplitude discriminate between healthy vs diseased systems. To monitor these mechanical changes in the in vitro model we will use Brillouin microscopy in a biological context. This technique is based on the propagation of acoustic waves in the system to characterise mechanical properties and will allow detailed mapping of stiffness of the bone marrow model as a function of time - importantly in a non-invasive way. Moreover, the level of mechanical stimulation will be dependent on the readout provided by Brillouin microscopy that will feed into a control system to alter the level of the mechanical vibrational stimulation imposed on the bone marrow model. We will develop the technology to have a robust on-chip system that includes the bone marrow model and integrates mechanical stimulation.
We will use the technology in two clinical applications: (1) to assess whether the technology can predict leukaemia which can be induced as an off-target effect of the treatment (chemotherapy/radiotherapy) of solid tumours and (2) to assess whether the technology can predict malignant transformations in heaematopoeitic stem cells that happes with age, eventally leading to leukaemia.
We will focus on leukaemia, a cancer that originates in the bone marrow, as normal haematopoietic stem cells, which play the essential role of making our blood, start a malignant transformation giving rise to leukemic stem cells. We have demonstrated that healthy cells and pre-malignant/malignant cells respond differently to mechanical stimulation. This project will develop an in vitro model of the bone marrow using soft hydrogels with defined mechanical and biochemical properties that host mesenchymal stem cells and hematopoietic (or leukemic) stem cells, as are found together in the marrow. We will investigate how external mechanical stimulation of the model using nanoscale vibration of controlled frequency and amplitude discriminate between healthy vs diseased systems. To monitor these mechanical changes in the in vitro model we will use Brillouin microscopy in a biological context. This technique is based on the propagation of acoustic waves in the system to characterise mechanical properties and will allow detailed mapping of stiffness of the bone marrow model as a function of time - importantly in a non-invasive way. Moreover, the level of mechanical stimulation will be dependent on the readout provided by Brillouin microscopy that will feed into a control system to alter the level of the mechanical vibrational stimulation imposed on the bone marrow model. We will develop the technology to have a robust on-chip system that includes the bone marrow model and integrates mechanical stimulation.
We will use the technology in two clinical applications: (1) to assess whether the technology can predict leukaemia which can be induced as an off-target effect of the treatment (chemotherapy/radiotherapy) of solid tumours and (2) to assess whether the technology can predict malignant transformations in heaematopoeitic stem cells that happes with age, eventally leading to leukaemia.
Organisations
- University of Glasgow (Lead Research Organisation)
- Medical Research Council (Co-funder)
- NHS AYRSHIRE AND ARRAN (Collaboration)
- University of Navarra Clinic (Collaboration)
- University of Glasgow (Collaboration)
- Cell Guidance Systems Ltd (Collaboration, Project Partner)
- LightMachinery (Collaboration)
- Queen Elizabeth University Hospital (Collaboration)
- Nikon (Collaboration)
- Novartis (Collaboration)
- Bioascent (Collaboration, Project Partner)
- Institute for Bioengineering of Catalonia (Collaboration)
- ETH Zurich (Collaboration)
- Blood Cancer UK (Collaboration)
- University of Perugia (Collaboration)
- NHS Scotland (Project Partner)
- Nikon (International) (Project Partner)
- Inst for Bioengineering of Catalonia (Project Partner)
- University of Perugia (Project Partner)
- Beatson West of Scotland Cancer Centre (Project Partner)
- LightMachinery Inc (Project Partner)
- Novartis Pharma AG (Project Partner)
- ScreenIn3D (Project Partner)
- NHS GREATER GLASGOW AND CLYDE (Project Partner)
- NHS Ayrshire & Arran (Project Partner)
Publications
Barcelona-Estaje E
(2024)
N-cadherin crosstalk with integrin weakens the molecular clutch in response to surface viscosity.
in Nature communications
Ciccone G
(2025)
Epithelial Cell Mechanoresponse to Matrix Viscoelasticity and Confinement Within Micropatterned Viscoelastic Hydrogels
in Advanced Science
Oliva M
(2024)
Piezo1 is a mechanosensor of soft matrix viscoelasticity
Rodgers C
(2025)
3D mechanical mapping of spherioids using Brillouin spectroscopy (Currently being peer-reviewed)
in Journal of Visualised experiments
| Description | Bioascent |
| Organisation | BioAscent |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials, secondment of staff, etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | Blood Cancer UK |
| Organisation | Blood Cancer UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Our project team reports on our progress towards revolutionising predictive medicine by harnessing mechanobiology to assess the risk of leukaemia in patients. We are focused on developing methodologies for detecting early-stage cancer through innovative cell stimulation techniques, with the ultimate goal of enabling personalised, efficient, and successful treatments. |
| Collaborator Contribution | Our partner, a valued member of the International Advisory Board (IAB), supports the project by providing strategic and insightful feedback, along with expert guidance, to ensure meaningful development against our deliverables, contributing to the evolution of healthcare in cancer assessment. |
| Impact | Dr. Lisa Whittaker represents Blood Cancer UK within our project and actively participates in the project's International Advisory Board meetings, offering strategic direction. Her feedback on our progress is invaluable, enabling the project team to make informed improvements in the research and development of methodologies that utilise mechanobiology to assess the risk of leukaemia in patients. |
| Start Year | 2024 |
| Description | Cell Guidance Systems Ltd |
| Organisation | Cell Guidance Systems Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | Clínica Universidad de Navarra |
| Organisation | University of Navarra Clinic |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | Our project team reports on our progress towards revolutionising predictive medicine by harnessing mechanobiology to assess the risk of leukaemia in patients. We are focused on developing methodologies for detecting early-stage cancer through innovative cell stimulation techniques, with the ultimate goal of enabling personalised, efficient, and successful treatments. |
| Collaborator Contribution | Our partner, a valued member of the International Advisory Board (IAB), supports the project by providing strategic and insightful feedback, along with expert guidance, to ensure meaningful development against our deliverables, contributing to the evolution of healthcare in cancer assessment. |
| Impact | Prof. Prósper Cardoso represents Clínica Universidad de Navarra within our project and actively participates in the project's International Advisory Board meetings, offering strategic direction. His feedback on our progress is invaluable, enabling the project team to make informed improvements in the research and development of methodologies that utilise mechanobiology to assess the risk of leukaemia in patients. |
| Start Year | 2024 |
| Description | ETH Zürich |
| Organisation | ETH Zurich |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | Our project team reports on our progress towards revolutionising predictive medicine by harnessing mechanobiology to assess the risk of leukaemia in patients. We are focused on developing methodologies for detecting early-stage cancer through innovative cell stimulation techniques, with the ultimate goal of enabling personalised, efficient, and successful treatments. |
| Collaborator Contribution | Our partner, a valued member of the International Advisory Board (IAB), supports the project by providing strategic and insightful feedback, along with expert guidance, to ensure meaningful development against our deliverables, contributing to the evolution of healthcare in cancer assessment. |
| Impact | Prof. Viola Vogel represents ETH Zürich within our project and actively participates in the project's International Advisory Board meetings, offering strategic direction. Her feedback on our progress is invaluable, enabling the project team to make informed improvements in the research and development of methodologies that utilise mechanobiology to assess the risk of leukaemia in patients. |
| Start Year | 2024 |
| Description | Inst for Bioengineering of Catalonia |
| Organisation | Institute for Bioengineering of Catalonia |
| Country | Spain |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | LightMachinery Inc |
| Organisation | LightMachinery |
| Country | Canada |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | NHS Affiliated (x3) |
| Organisation | NHS Ayrshire and Arran |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | NHS Affiliated (x3) |
| Organisation | Queen Elizabeth University Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | NHS Affiliated (x3) |
| Organisation | University of Glasgow |
| Department | NHS Research Scotland GGC Biorepository |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | Nikon UK Ltd |
| Organisation | Nikon |
| Department | Nikon UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | Novartis Pharma AG |
| Organisation | Novartis |
| Department | Novartis Pharma Switzerland |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | University of Perugia |
| Organisation | University of Perugia |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Our collaboration with this external project partner is still in its early stages of discussion. We are actively engaging and reaching out with all our external partners to explore how we can leverage their expertise within our project. Our aim is to enhance the training of a cohort of Postdoctoral Research Associates (PDRAs) and PhD students, positioning them as the next generation of leaders in the field. |
| Collaborator Contribution | In their letter of support, submitted prior to the project being awarded, the potential partner expressed an interest in making an in-kind contribution (the estimated amount has already been stated in the partners' details section above), primarily through staff time, with the possibility of other resources, such as accessing facilities, materials etc. Therefore, once we have made progress towards establishing a formal agreement, this section will be updated accordingly. |
| Impact | Please refer to above information as our collaboration with this external project partner is still in its early stages of discussion. |
| Start Year | 2024 |
| Description | Attendance at the Patient and Public Involvement and Engagement in Birmingham in Feb 2025 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | The Patient and Public Involvement and Engagement (PPIE) event was instrumental in enhancing our understanding of the landscape surrounding bone regeneration and facilitated valuable connections that will support the successful implementation of our project goals. The diverse participation of the Mechanomeds team across different themes highlights our commitment to a collaborative and multidisciplinary approach in advancing healthcare technologies. |
| Year(s) Of Engagement Activity | 2025 |
